Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaMichael J. Keating, Hagop M. Kantarjian, Susan O’Brien et al.|Journal of Clinical Oncology|2005Cited by 951
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19Derek C. Angus, Balasubramanian Venkatesh, Kelsey Linstrum et al.|JAMA|2020Cited by 884
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and DesignDerek C. Angus, Steven Webb, Scott Berry et al.|Annals of the American Thoracic Society|2020Cited by 449
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trialLy‐Mee Yu, Mona Bafadhel, Jienchi Dorward et al.|The Lancet|2021Cited by 310
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary reportChristopher W. Seymour, Anthony Gordon, Paul Mouncey et al.|medRxiv|2021Cited by 137